CRNX · Crinetics Pharmaceuticals, Inc.
$84.95
+0.00% 2-day
End-of-day data · updated 2026-09-11
Market cap
$9B
Enterprise value
$8B
Trailing P/E
—
Forward P/E
-21.2
Dividend yield
—
Beta
0.09
Avg volume
4M
Employees
1K
Daily Change %
0.00%
5 Days Change
0.13%
10 Days Change
0.20%
30 Days Change
1.30%
60 Days Change
101.16%
Month to Day Change
0.00%
Year to Day Change
82.49%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Technical data is temporarily unavailable for CRNX.
Analyst sentiment over time — CRNX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-28
Latest call per bank · past 12 months
UBS
Neutral$85.00
+0.1% vs priceJefferies
Hold$85.00
+0.1% vs priceGoldman Sachs
Buy$67.00
-21.1% vs priceMorgan Stanley
Overweight$80.00
-5.8% vs priceJP Morgan
Overweight$52.00
-38.8% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-28 | UBS | Downgrade | Buy → Neutral | $55.00 → $85.00 |
| 2026-07-08 | TD Cowen | Downgrade | Buy → Hold | $0.00 |
| 2026-07-08 | Evercore ISI Group | Downgrade | Outperform → In-Line | $88.00 → $85.00 |
| 2026-07-07 | Jones Trading | Downgrade | Buy → Hold | $0.00 → $85.00 |
| 2026-07-07 | Jefferies | Downgrade | Buy → Hold | $55.00 → $85.00 |
| 2026-07-07 | Oppenheimer | Downgrade | Outperform → Perform | $0.00 |
| 2026-07-07 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | $0.00 |
| 2026-07-07 | HC Wainwright & Co. | Downgrade | Buy → Neutral | $81.00 → $85.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
CRNX Price Chart
Loading chart for CRNX…
Fundamentals
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnant, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and cushing's disease; and CRN09682, a nonpeptide drug conjugate for SST2 positive solid tumors. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease; and SST3 Agonist program for the treatment of polycystic kidney disease, as well as Oral GLP-1 and Oral GIP nonpeptides for the treatment of obesity. The company has an agreement with Sanwa Kagaku Kenkyusho Co., Ltd to develop and commercialize Paltusotine in Japan, and Cellular Longevity, Inc. to develop and commercialize CRN01941, a somatostatin receptor type 2 agonist. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.